<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-4-6">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
			</div>

			<div class="slide-title red">
				Adverse events of special interest
			</div>


			<div class="content-container">

				<ul>
					<li><span>In previous studies of patients with ITP and chronic hepatitis C viral infection, the following AEs occurred more frequently in the eltrombopag treatment arm:<sup>1</sup></span>
						<ul>
							<li><span>Hepatobiliary abnormalities/hepatotoxicity</span></li>
							<li><span>Hepatic decompensation (chronic hepatitis C viral only)</span></li>
							<li><span>Thromboembolic complications</span></li>
						</ul>
					</li>
					<li><span>Therefore, these events and the rate of cytogenetic abnormalities were evaluated in the pivotal phase II refractory aplastic anaemia study<sup>2</sup></span></li>
					<li><span>Hepatobiliary AEs were reported in 37% of patients (16/43)<sup>2</sup></span>
						<ul>
							<li><span>Of these, 13 patients had no changes to eltrombopag dosing, two interrupted treatment due to elevated liver function test parameters, and one discontinued treatment due to hepatitis B</span></li>
							<li><span>Most reported hepatobiliary AEs were mild to moderate in severity</span></li>
						</ul>
					</li>
					<li><span>No thromboembolic AEs were reported during the study<sup>2</sup></span></li>
					<li><span>New cytogenetic abnormalities were reported in 19% of patients (8/43)<sup>3</sup></span>
						<ul>
							<li><span>Six were non-responders to eltrombopag</span></li>
						</ul>
					</li>
				</ul>

			</div>

		</div>




		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>GlaxoSmithKline. Eltrombopag tablets for oral use. Prescribing Information (draft). 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Desmond R et al. Blood 2014;123:1818</span></li>
			</ol>

		</div>


		

	</div>
</div>